(Q45871401)

17 December 2017

title

Clinical evaluation of a recombinant factor VIII preparation (Kogenate) in previously untreated patients with hemophilia A. (English)

1 reference

17 December 2017

antihemophilic factor, human recombinant

main subject

hemophilia

0 references

Coagulation factor VIII

0 references

hemophilia A

0 references

1 reference

A Yoshioka

1

1 reference

17 December 2017

K Fukutake

2

1 reference

17 December 2017

J Takamatsu

3

1 reference

17 December 2017

A Shirahata

4

1 reference

17 December 2017

Kogenate Post-Marketing Surveillance Study Group

5

1 reference

17 December 2017

publication date

1 December 2003

1 reference

17 December 2017

International Journal of Hematology

published in

1 reference

17 December 2017

volume

78

1 reference

17 December 2017

issue

5

1 reference

17 December 2017

page(s)

467-474

1 reference

17 December 2017

https://scigraph.springernature.com/pub.10.1007/bf02983823

exact match

0 references

cites work

Incidence of inhibitors in haemophilia A patients--a review of recent studies of recombinant and plasma-derived factor VIII concentrates

1 reference

12 December 2020

Treatment of hemophilia A with a highly purified factor VIII concentrate prepared by anti-FVIIIc immunoaffinity chromatography

1 reference

12 December 2020

Incidence of inhibitors in patients with severe and moderate hemophilia A treated with factor VIII concentrates

1 reference

12 December 2020

The natural history of factor VIII:C inhibitors in patients with hemophilia A: a national cooperative study. II. Observations on the initial development of factor VIII:C inhibitors

1 reference

12 December 2020

Antibodies to heterologous proteins in hemophilia A patients receiving recombinant factor VIII (Recombinate)

1 reference

12 December 2020

Letter: A more uniform measurement of factor VIII inhibitors

1 reference

12 December 2020

Characterization of the human factor VIII gene.

1 reference

12 December 2020

Prevalence of inhibitors in a population of 3435 hemophilia patients in France. French Hemophilia Study Group

1 reference

12 December 2020

A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in The Netherlands. Dutch Hemophilia Study Group

1 reference

12 December 2020

Viral safety and inhibitor development associated with monoclonal antibody-purified F VIII C.

1 reference

12 December 2020

Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. recombinant Factor VIII Study Group

1 reference

12 December 2020

Measurement of anti-factor VIII IgG, IgG4 and IgM alloantibodies in previously untreated hemophilia A patients treated with recombinant factor VIII. Kogenate Japanese Clinical Study Group

1 reference

12 December 2020

The incidence of factor VIII inhibitors in the United Kingdom, 1990-93. Inhibitor Working Party. United Kingdom Haemophilia Centre Directors Organization

1 reference

12 December 2020

Expression of active human factor VIII from recombinant DNA clones

1 reference

12 December 2020

Clinical evaluation of recombinant human factor VIII (BAY w 6240) in the treatment of hemophilia A

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF02983823

1 reference

17 December 2017

Dimensions Publication ID

0 references

1 reference

17 December 2017